Liraglutide and insulin detemir combination therapy to be investigated for myocardial glucose uptake in T2D
Background
Type 2 diabetes (T2D) is characterized by impaired glucose metabolism, significantly impacting various organs, including the heart. While GLP-1 receptor (GLP-1R) agonists like liraglutide offer substantial glucose and weight-lowering benefits, emerging evidence also suggests direct cardioprotective effects independent of systemic glucose control. However, the precise mechanisms and the potential for synergistic action with insulin on myocardial fuel selection in T2D patients remain underexplored. Understanding this cooperation could optimize therapeutic strategies for cardiac health in diabetes.
Study Design
A randomized clinical trial will enroll 27 Type 2 diabetic subjects (HbA1c 7.5-9.5%) currently on diet/exercise or oral antidiabetics, all on a background of metformin 2000 mg per day. Subjects will be randomized to one of three treatment groups (n=9 each): insulin detemir, liraglutide, or liraglutide plus detemir. Treatment duration is 3 months. The primary endpoint, myocardial fuel selection, will be measured by PET scans under fasting conditions following the final treatment injection.
Why It Matters
This study aims to clarify how liraglutide and insulin detemir interact to influence myocardial glucose uptake in T2D patients. If synergy is demonstrated, it could lead to optimized combination therapies for improving cardiac metabolic health beyond glycemic control. Such findings could inform future clinical guidelines, potentially altering how GLP-1R agonists and insulin are prescribed together to mitigate diabetic cardiomyopathy risk. The results could provide a mechanistic basis for the observed cardioprotective effects of GLP-1R agonists.
liraglutide
insulin detemir
type 2 diabetes
myocardial glucose uptake
cardioprotection
clinical trial